Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Ligand Pharma Slips as Analyst Cuts Rating

By Pharmaceutical Processing | August 2, 2013

Shares of Ligand Pharmaceuticals Inc. fell Friday after an analyst downgraded the company, citing the run-up in its stock price and setbacks for two drug candidates.

THE SPARK: Cantor Fitzgerald analyst Irina Rivkind downgraded the shares to “Sell” from “Hold,” noting that the company’s partners have stopped work on two late-stage experimental drugs.

Ligand said Thursday that Medicines Co. has ended work on intravenous version of the blood thinner Plavix. Ligand will get the rights to the drug back and can continue development or look for a new partner. Ligand also said Merck & Co. has stopped development of its leukemia drug dinaciclib.

Rivkind raised her price target by $1 to $37, but said the company’s current share price reflects a “best-case scenario” that may not pan out.

THE BIG PICTURE: The San Diego company said Thursday morning that it posted a second-quarter profit of $6.1 million, or 30 cents per share, and its revenue rose 67 percent to $9.6 million. Royalty payments rose 63 percent to $4.9 million.

The company gets royalty payments on drugs including GlaxoSmithKline’s Promacta and Onyx Pharmaceuticals Inc.’s multiple myeloma treatment Kyprolis. Ligand also has partnerships with Hospira Inc., Spectrum Pharmaceuticals Inc., and Sanofi.

SHARE ACTION: Ligand shares lost $2.43, or 5 percent, to $46.59 on Friday. Even with that decline the stock has more than doubled in value in 2013.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE